Jade Biosciences, Inc.
▲ 0 upgrades / ▼ 0 downgrades / 2 reiterations from 2 firms
Nov 11, 2026 (16 days)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 1, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Oct 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 11, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 10, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jun 15, 2026 | UBS | initiate | — → Buy | — | 54% |
| Jun 2, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jun 1, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jun 1, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 27, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| May 11, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 11, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 27, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 16, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Mar 11, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 9, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jan 7, 2026 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
| Nov 25, 2025 | Clear Street | initiate | — → Buy | $25 | 48% |
| Nov 18, 2025 | Guggenheim | maintain | Buy → Buy | $17 | 52% |
| Oct 9, 2025 | BTIG | initiate | — → Buy | $28 | 52% |
| Aug 14, 2025 | Wedbush | maintain | Outperform → Outperform | $18 | 58% |
| Jun 16, 2025 | Guggenheim | upgrade | Neutral → Buy | $14 | 52% |
| May 15, 2025 | Wedbush | reiterate | Outperform → Outperform | $17 | 58% |
| May 7, 2025 | Wedbush | initiate | — → Outperform | $17 | 58% |
No cross-platform signals in the last 90 days